-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Evolving Standards of Care
-
From Sequencing to Treatment: The Role of Comprehensive Genome Profiling, Molecular Tumor Boards in Advanced-Stage NSCLC
Citing data from the FPG500 program, Drs. Antonio Vitale and Emilio Bria write that integrating genome profiling and molecular tumor boards into daily practice is feasible and yields measurable survival benefits for patients with actionable molecular alterations.
-
Don’t Go Breaking My Heart: Cardiac Toxicity Prevention in Lung Cancer and Management Through Multidisciplinary Care
Dr. Arya Amini highlights several guidelines that can inform cardiac surveillance care for patients with lung cancer following completion of radiation treatment.
-
Keynote Address Explores the Future of Biomarkers in the ADC Era
During his lecture at the 2026 European Lung Cancer Congress, Dr. Fred R. Hirsch outlined the current state of knowledge in ADC research, as well as what still needs to be learned.
-
European Framework Aims to Provide Guidance on the Development, Clinical Applicability of AI-Based Biomarkers
During ELCC 2026, Dr. Mihaela Aldea discussed how the ESMO requirements can be used to validate AI-driven biomarkers, while emphasizing the importance of continuous post-validation monitoring for data drift.
-
A Shift in Focus: Real-World Data Reframe the Value of N1 Nodal Assessments in Resection
Dr. Christopher Seder explores how a more extensive N1 station assessment allows thoracic oncologists and pathologists to find more unrecognized cancer and improve staging accuracy.
-
Session to Address New Realities, Unique Patient Needs in Lung Cancer Care
On Thursday at ELCC 2026, Dr. Narjust Florez will emphasize the importance of earlier diagnosis and personalized support for younger patients with lung cancer.
-
Personalized Lung Cancer Therapies: One Size Does Not Fit All
During the TTLC 2026 Opening Keynote, Dr. John V. Heymach said personalizing lung cancer therapies will require disentangling heterogeneity to understand the underlying factors driving the disease in each patient.
-
Advocate Calls for Stronger Patient Partnerships in Clinical Research
Jane Perlmutter, a survivor of multiple cancers, encouraged investigators to involve patient advocates at every stage of research during the TTLC 2026 Patient Advocate Session.
-
Debate Centers on Whether RAS Inhibitors Will Become First-Line Therapy by 2026
Drs. Ferdinandos Skoulidis and Marina C. Garassino went head-to-head over whether emerging KRAS combination data support first-line adoption by year’s end.
-
Research to Watch: Aumolertinib Delivers Notable Performance as an EGFR-Targeted Therapy in the Adjuvant Setting
Results from the phase III ARTS trial illustrate the potential of aumolertinib as adjuvant therapy for patients with resected EGFR-mutated NSCLC.